Nothing Special   »   [go: up one dir, main page]

CO6190533A2 - Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido - Google Patents

Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido

Info

Publication number
CO6190533A2
CO6190533A2 CO09013387A CO09013387A CO6190533A2 CO 6190533 A2 CO6190533 A2 CO 6190533A2 CO 09013387 A CO09013387 A CO 09013387A CO 09013387 A CO09013387 A CO 09013387A CO 6190533 A2 CO6190533 A2 CO 6190533A2
Authority
CO
Colombia
Prior art keywords
compound
patient
effective amount
lower airways
diseases
Prior art date
Application number
CO09013387A
Other languages
English (en)
Inventor
Pauline C Ting
Joe F Lee
Kung I Feng
Michael R Reeder
Scott Trzaska
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO6190533A2 publication Critical patent/CO6190533A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- El compuesto que tiene la fórmula estructural2.- Un método para tratar enfermedades obstructivas de las vías aéreas superiores o inferiores en un paciente que necesita tal tratamiento que comprende administrar por inhalación a dicho paciente una cantidad eficaz del compuesto de la reivindicación 1. 3.- El método de la reivindicación 2 en el cual la enfermedad tratada es asma o enfermedad pulmonar obstructiva crónica. 4.- Un método para tratar enfermedades obstructivas de las vías aéreas superiores o inferiores en un paciente que necesita tal tratamiento que comprende administrar por inhalación a dicho paciente una cantidad eficaz de una combinación del compuesto de la reivindicación 1 y al menos un agente adicional útil para tratar enfermedades obstructivas de las vías aéreas superiores o inferiores. 5.- El método de la reivindicación 4 en el cual la enfermedad tratada es asma o enfermedad pulmonar obstructiva crónica. 6.- El método de la reivindicación 4 en el cual el agente adicional se selecciona del grupo integrado por beta-agonistas, antagonistas muscarínicos y corticoesteroides. 7.- Una composición farmacéutica inhalable que comprende una cantidad eficaz del compuesto de la reivindicación 1. 8.- Una composición farmacéutica inhalable que comprende una cantidad eficaz de una combinación del compuesto de la reivindicación 1 y al menos un agente adicional útil para tratar enfermedades obstructivas de las vías aéreas superiores o inferiores.
CO09013387A 2006-07-11 2009-02-11 Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido CO6190533A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83005706P 2006-07-11 2006-07-11

Publications (1)

Publication Number Publication Date
CO6190533A2 true CO6190533A2 (es) 2010-08-19

Family

ID=38895717

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09013387A CO6190533A2 (es) 2006-07-11 2009-02-11 Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido

Country Status (22)

Country Link
US (1) US7919505B2 (es)
EP (1) EP2038277A2 (es)
JP (2) JP5097774B2 (es)
KR (1) KR20090026217A (es)
CN (1) CN101547920B (es)
AR (1) AR061890A1 (es)
AU (1) AU2007273007B2 (es)
BR (1) BRPI0712915A2 (es)
CA (1) CA2657902A1 (es)
CL (1) CL2007002020A1 (es)
CO (1) CO6190533A2 (es)
EC (1) ECSP099045A (es)
IL (1) IL196402A0 (es)
MX (1) MX2009000460A (es)
NO (1) NO20090646L (es)
NZ (1) NZ574070A (es)
PE (2) PE20080550A1 (es)
RU (1) RU2009104346A (es)
SG (1) SG173366A1 (es)
TW (1) TW200813040A (es)
WO (1) WO2008008327A2 (es)
ZA (1) ZA200900208B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511062B2 (en) * 2004-05-18 2009-03-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
WO2008021235A2 (en) * 2006-08-14 2008-02-21 Schering Corporation Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives
CA2692776A1 (en) * 2007-07-10 2009-01-15 Schering Corporation Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof
WO2009009003A1 (en) * 2007-07-10 2009-01-15 Schering Corporation Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof
JP5709101B2 (ja) * 2010-09-01 2015-04-30 東レ・ファインケミカル株式会社 ヒドロキシプロリン誘導体の製造法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
SK283162B6 (sk) 1996-05-20 2003-03-04 Darwin Discovery Limited Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom
CA2252501A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
US20050017134A1 (en) 2003-07-24 2005-01-27 Hooper Patricia E. Glass and bottle holders
US7511062B2 (en) * 2004-05-18 2009-03-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form

Also Published As

Publication number Publication date
PE20080550A1 (es) 2008-06-13
NZ574070A (en) 2011-12-22
ECSP099045A (es) 2009-02-27
WO2008008327A2 (en) 2008-01-17
BRPI0712915A2 (pt) 2012-10-09
RU2009104346A (ru) 2010-08-20
CL2007002020A1 (es) 2008-02-22
ZA200900208B (en) 2010-01-27
SG173366A1 (en) 2011-08-29
AU2007273007B2 (en) 2012-11-01
CN101547920A (zh) 2009-09-30
JP2009542811A (ja) 2009-12-03
TW200813040A (en) 2008-03-16
CA2657902A1 (en) 2008-01-17
JP2012214482A (ja) 2012-11-08
WO2008008327A3 (en) 2008-03-06
US7919505B2 (en) 2011-04-05
US20080027101A1 (en) 2008-01-31
MX2009000460A (es) 2009-01-27
AR061890A1 (es) 2008-10-01
KR20090026217A (ko) 2009-03-11
CN101547920B (zh) 2012-06-27
IL196402A0 (en) 2009-09-22
AU2007273007A1 (en) 2008-01-17
PE20110391A1 (es) 2011-06-22
JP5097774B2 (ja) 2012-12-12
EP2038277A2 (en) 2009-03-25
NO20090646L (no) 2009-04-07

Similar Documents

Publication Publication Date Title
BRPI0606736A2 (pt) combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas
SMT201300101B (it) Un'emulsione del tipo acqua in olio per il trattamento di una malattia dell'occhio
BRPI0710485B8 (pt) composições líquidas úteis no tratamento de doenças respiratórias
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR042578A1 (es) Inhibidores de la sintesis de mucina
BR112015014592A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um humano
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
AR060089A1 (es) Tratamiento del dolor
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR0212251A (pt) Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica, método para o tratamento preventivo e/ou terapêutico de uma doença ou distúrbio decorrente de proliferação celular anormal ou imprópria, e, uso do dito composto ou de um sal farmaceuticamente aceitável do mesmo
CO6190533A2 (es) Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
CO5550426A2 (es) Novedoso metodo terapeutico
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
PE20091672A1 (es) Nueva dosificacion y formulacion
BR112014027884A2 (pt) combinações farmacêuticas para tratamento de distúrbios metabólicos
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
AR054411A1 (es) Combinacion farmaceutica que comprende un compuesto olefinico de 8- azoniabiciclo [ 3.2.1] octano y uno o mas ingredientes terapeuticos distintos, composicion farmaceutica que la comprende y uso de dichos componentes para prepararla

Legal Events

Date Code Title Description
FC Application refused